EZH2 and leukemia: RDS 3434 has been shown to be specifically active only against EZH2, and to be a selective EZH2 inhibitor in human leukemia cells where it induced heavy cell death in a dose-dependent manner, coupled with a reduction of H3K27me3 levels, without affecting EZH2 protein level [24].